Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCy vs Thymoglobulin for GVHD Prophylaxis in MPN/MDS
NCT02627573Phase 2Terminated
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jul 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD) (2 arms), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Incidence of primary graft failure at 60 days. Started Jul 2015; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02627573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627573.